Uveal Melanoma Clinical Trials

120 clinical trials for Uveal Melanoma across international registries, including 28 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF NEOADJUVANT DAROVASERTIB IN SUBJECTS WITH PRIMARY NON-METASTATIC UVEAL MELANOMA (OptimUM-10) — RECRUITING · PHASE3
• A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma — RECRUITING · PHASE1
• Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma — RECRUITING · PHASE1
• Adjuvant Tebentafusp in High Risk Ocular Melanoma — RECRUITING · PHASE3
• Adjuvant Quisinostat in High-Risk Uveal Melanoma — RECRUITING · PHASE2
• Neoadjuvant Darovasertib in Primary Uveal Melanoma — RECRUITING · PHASE3
• Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma — RECRUITING · NA
• Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors — RECRUITING · PHASE1
• Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver — RECRUITING · NA
• Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome — RECRUITING
• Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma — RECRUITING · PHASE2
• Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects — RECRUITING
• Neoadjuvant nivolumab and ipilimumab for patients with high-risk uveal melanoma — RECRUITING · PHASE1
• A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit — RECRUITING · PHASE1
• Melphalan Chemoreduction for Ocular Melanoma — RECRUITING · PHASE1
• Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) — RECRUITING · NA
• A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF NEOADJUVANT DAROVASERTIB IN SUBJECTS WITH PRIMARY NON-METASTATIC UVEAL MELANOMA (OPTIMUM-10) — RECRUITING · PHASE3
• Adding IL-2 to Tebentafusp to Eradicate Cancer Progression — RECRUITING · PHASE1
• Adjuvant Melatonin for Uveal Melanoma — RECRUITING · PHASE3
• PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases — RECRUITING · PHASE3
• IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) — RECRUITING
• (NEO)ADJUVANT IDE196 (DAROVASERTIB) IN PATIENTS WITH LOCALIZED OCULAR MELANOMA — RECRUITING
• Retrospective Register for Uveal Melanoma — RECRUITING
• A PHASE 1/2 STUDY OF IDE196 IN PATIENTS WITH SOLID TUMORS HARBORING GNAQ/11 MUTATIONS OR PRKC FUSIONS — RECRUITING · PHASE1
• A PHASE I/II, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF IMCGP100 USING THE INTRA-PATIENT ESCALATION DOSING REGIMEN PATIENTS WITH ADVANCED UVEAL MELANOMA — RECRUITING · PHASE1
• A PHASE II RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF IMCGP100 COMPARED WITH INVESTIGATOR'S CHOICE IN HLA-A*0201 POSITIVE PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED UVEAL MELANOMA — RECRUITING · PHASE2
• A multicenter, randomized, two-armed, open-label Phase III study to evaluate the vaccination with tumor RNA-loaded autologous dendritic cells versus observation of patients with resected monosomy 3 uveal melanoma — RECRUITING
• Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma — RECRUITING
• A Prospective Natural History Study in Uveal Melanoma — ACTIVE_NOT_RECRUITING
• Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma — NOT_YET_RECRUITING · PHASE1
• A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma — ACTIVE_NOT_RECRUITING · PHASE3
• A Phase II Study of BVD-523 in Metastatic Uveal Melanoma — TERMINATED · PHASE2
• A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF ADJUVANT DAROVASERTIB AND CRIZOTINIB IN PARTICIPANTS WITH PRIMARY NON-METASTATIC UVEAL MELANOMA (OPTIMUM-11) — NOT_YET_RECRUITING · PHASE3
• EORTC 2022-MG: Adjuvant tebentafusp (IMCgp100) versus observation in HLA-A*02:01 positive patients following definitive treatment of high-risk uveal melanoma: an EORTC randomized phase III study (ATOM Trial) — TERMINATED · PHASE3
• A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) — ACTIVE_NOT_RECRUITING · PHASE1
• Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma — ACTIVE_NOT_RECRUITING · PHASE2
• Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients — ACTIVE_NOT_RECRUITING
• Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma — ACTIVE_NOT_RECRUITING · PHASE1
• Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma — COMPLETED · PHASE1
• Psychoeducation for Uveal Melanoma — ACTIVE_NOT_RECRUITING · NA
• Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma — COMPLETED · PHASE2
• (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma — ACTIVE_NOT_RECRUITING · PHASE2
• Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination — COMPLETED · PHASE2
• Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy — ACTIVE_NOT_RECRUITING · PHASE2
• Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma — COMPLETED · PHASE3
• A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase 1 Study of [225Ac]-FPI-1434 Injection — TERMINATED · PHASE1
• A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors — ACTIVE_NOT_RECRUITING
• (Neo)adjuvant IDE196 (Darovasertib) in Patients with Localized Ocular Melanoma — TERMINATED · PHASE2

Refine this search